Table 1.
Baseline characteristic of FRESCO compared to other TKIs group from real-world data before and after matching.
| Before PSM | After PSM | Statistical test applied | ||||||
|---|---|---|---|---|---|---|---|---|
| Variables | Other TKIs N (%) | Fruquintinib N (%) | p | Other TKIs N (%) | Fruquintinib N (%) | p | ||
| N | 257 | 278 | 128 | 128 | ||||
| Age (mean (SD)) | 57.35 (10.24) | 54.33 (10.70) | 0.001 | 56.15 (10.33) | 56.09 (10.94) | 0.967 | t-test | |
| Age group (%) | <65 years | 188 (73.2) | 228 (82.0) | 0.014 | 99 (77.3) | 96 (75.0) | 0.66 | Pearson Chi-square test |
| ≥65 years | 69 (26.8) | 50 (18.0) | 29 (22.7) | 32 (25.0) | ||||
| Sex (%) | F | 97 (37.7) | 120 (43.2) | 0.202 | 60 (46.9) | 50 (39.1) | 0.207 | Pearson Chi-square test |
| M | 160 (62.3) | 158 (56.8) | 68 (53.1) | 78 (60.9) | ||||
| Time from first diagnosis to randomization (median [IQR])* | 20.59 | 21.40 | 26 | 18.4 | Wilcoxon rank-sum test | |||
| [13.28, 32.95] | [14.20, 35.10] | 0.456 | [15.40, 38.42] | [13.40, 28.85] | 0.039 | |||
| Time from first diagnosis to randomization group (%) | ≤18 months | 109 (42.4) | 116 (41.7) | 0.624 | 43 (33.6) | 62 (48.4) | 0.016 | Pearson Chi-square test |
| >18 months | 148 (57.6) | 161 (57.9) | 85 (66.4) | 66 (51.6) | ||||
| Colorectal cancer stage at first diagnosis (%) | Stage I | 2(0.8) | 8 (2.9) | 1 (0.8) | 2 (1.6) | Pearson Chi-square test | ||
| Stage II | 23 (8.9) | 34 (12.2) | 17 (13.3) | 12 (9.4) | ||||
| Stage III | 58 (22.6) | 118 (42.4) | <0.001 | 36 (28.1) | 51 (39.8) | 0.005 | ||
| Stage IV | 143 (55.6) | 117 (42.1) | 60 (46.9) | 62 (48.4) | ||||
| Missing | 31 (12.1) | 1 (0.4) | 14 (10.9) | 1 (0.8) | ||||
| Primary tumor location (%)* | Left | 201 (78.2) | 214 (77.0) | 0.545 | 102 (79.7) | 101 (78.9) | 0.877 | Pearson Chi-square test |
| Right | 53 (20.6) | 56 (20.1) | 26 (20.3) | 27 (21.1) | ||||
| Primary disease site (%)* | Colon | 153 (59.5) | 147 (52.9) | 70 (54.7) | 64 (50.0) | Pearson Chi-square test | ||
| Rectal | 102 (39.7) | 125 (45.0) | 0.163 | 58 (45.3) | 60 (46.9) | 0.116 | ||
| Colon-rectal | 2 (0.8) | 6 (2.2) | 0 (0.0) | 4 (3.1) | ||||
| Liver metastasis (%)* | Yes | 189 (73.5) | 185 (66.5) | 0.078 | 85 (66.4) | 97 (75.8) | 0.098 | Pearson Chi-square test |
| Lung metastasis (%)* | Yes | 129 (50.2) | 188 (67.6) | <0.001 | 75 (58.6) | 90 (70.3) | 0.05 | Pearson Chi-square test |
| Metastatic (%) | Single | 80 (31.1) | 13 (4.7) | <0.001 | 22 (17.2) | 12 (9.4) | 0.066 | Pearson Chi-square test |
| Multiple | 177 (68.9) | 265 (95.3) | 106 (82.8) | 116 (90.6) | ||||
| Prior surgery (%) | Yes | 154 (59.9) | 264 (95.0) | <0.001 | 84 (65.6) | 118 (92.2) | <0.001 | Pearson Chi-square test |
| Prior Radiation (%) | Yes | 47 (18.3) | 85 (30.6) | 0.001 | 32 (25.0) | 29 (22.7) | 0.66 | Pearson Chi-square test |
| Previous chemotherapy regimens (%)* | 2 or 3 | 228 (88.7) | 190 (68.3) | <0.001 | 102 (79.7) | 106 (82.8) | 0.522 | |
| >3 | 29 (11.3) | 88 (31.7) | 26 (20.3) | 22 (17.2) | Pearson Chi-square test | |||
| Chemotherapy and pharmacological treatment (%) | Yes | 257 (100.0) | 278 (100.0) | NA | 128 (100.0) | 128 (100.0) | NA | Pearson Chi-square test |
|
Prior use of VEGF inhibitors
(%)* |
Yes | 154 (59.9) | 84 (30.2) | <0.001 | 54 (42.2) | 57 (44.5) | 0.705 | Pearson Chi-square test |
|
Prior use of EGFR inhibitors
(%)* |
Yes | 71 (27.6) | 40 (14.4) | <0.001 | 30 (23.4) | 23 (18.0) | 0.28 | Pearson Chi-square test |
| Neither | 69 (26.8) | 167 (60.1) | 55 (43.0) | 57 (44.5) | ||||
| Prior chemotherapy with VEGF and EFGR inhibitors (%) | VEGF only | 117 (45.5) | 71 (25.5) | <0.001 | 43 (33.6) | 48 (37.5) | 0.737 | Pearson Chi-square test |
| EGFR only | 34 (13.2) | 27 (9.7) | 19 (14.8) | 14 (10.9) | ||||
| Both | 37 (14.4) | 13 (4.7) | 11 (8.6) | 9 (7.0) | ||||
CI, confidence interval; EGFR, epidermal growth factor receptor; F, females; M, males; N, number of patients; PSM, propensity score-matching; SD, standard deviation; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor.
* were the covariates that were used for propensity score matching.
NA, not applicable.